Spanish Red Biotech Pipeline

MSD

MK6482 + pembrolizumam / pembrolizumab + placebo

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Pembrolizumab + belzutifan vs pembrolizumab + placebo in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy
Phase: 3Phase III in Spain, 2Phase II, 1Phase I